The invention refers to the composition of the improved oral coating compression drug, which contains medically acceptable butadiene or its salts, and formaldehyde or its medically acceptable salts which can be used for the treatment of type 2 diabetes. The drug ingredient is obtained by wet particles, using a fine powder of ground formaldehyde and a low prostate load, consisting of a polymer, in this case povidona and magnesium stearate, as lubricating oil during compression. It has greatly improved people's understanding of it,At the same time, it can optimize the operating conditions. Compared with the two different active components, the improved drug components, including the combination of butadiene and formaldehyde, are transported in the form of covered sheet, without any difference in tube release (dissolution),On the other hand, the compressibility of particles and the cooling ability of compression are improved. The above factors make the improved components different from other components containing the same assets, and these components use a large number of precursors, so they are the main objects of the invention.La presente invención se refiere a una composición farmacéutica mejorada en la forma de comprimido oral recubierto, con Teneligliptina o sus sales farmacéuticamente aceptables y Metformina o sus sales farmacéuticamente aceptables para el tratamiento de diabetes mellitus tipo 2. Dicha composición farmacéutica es obtenida por granulación húmeda, utilizando Metformina molida a polvo fino y baja carga de excipientes, consistentes en un aglutinante, en este caso Povidona y Estearato de Magnesio como lubricante durante la compresión. El hecho de utilizar la Metformina molida, mejora notablemente la compresibilidad de la misma, permitiendo a su vez optimizar las condiciones operativas. La composición farmacéutica mejorada, comprendiendo la combinación de Teneligliptina y Metformina, comparada con ambos principios activos por separado, vehiculizados e
